Beyond glucose homeostasis, selective GLP-1 agonists have shown neuroprotective effects by mitigating AD neuropathology in preclinical studies and improving cognitive function in both preclinical and clinical studies, suggesting a potential influence on AD pathophysiology [1,13]. The gene discussed is GLP1R; the disease is Alzheimer disease.